Mineralys Therapeutics MLYS 深 滬
等待開盤 03-26 09:30:00 美东时间
24.62
+1.740
+7.60%
華盛通- 最 高24.64
- 今 開23.62
- 成交量 109.32万股
- 最 低 23.59
- 昨 收 22.88
- 總市值 19.48亿
- 52周最高 47.65
- 市盈率 靜 --
- 換手率 1.38%
- 52周最低 10.44
- 委 比 -89.06%
- 總股本 7914.00万
- 歷史最高 47.65
- 量 比 0.61
- 振 幅 4.59%
- 歷史最低 5.85
- 每 手 1
- 風險率 11.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics appoints Jeffrey A. Munsie as Chief Legal Officer, bringing over 25 years of biopharma legal experience. Munsie previously served as CLO at Orbital Therapeutics and held leadership roles at Concert Pharmaceuticals and Merrimack Pharmaceuticals. The company granted him stock options and restricted stock units under its 2025 Employment Inducement Incentive Award Plan. Mineralys is developing lorundrostat, an aldosterone synth...
03-24 12:00
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, a biopharmaceutical company focused on developing medicines for hypertension and related diseases, granted an inducement stock option award of 27,920 shares and an inducement restricted stock unit award of 20,940 shares to a new non-executive employee on March 16, 2026. The awards were made under the company's 2025 Employment Inducement Incentive Plan, with options vesting over four years and restricted stock units vesting...
03-16 20:05
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Mineralys Therapeutics Charts Path After NDA Acceptance
Mineralys Therapeutics, Inc. (($MLYS)) has held its Q4 earnings call. Read on f...
03-14 08:10
财报速睇 | Mineralys Therapeutics 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损1.55亿美元，同比亏损缩窄12.9%
华盛资讯3月13日讯，Mineralys Therapeutics公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损1.55亿美元，同比亏损缩窄12.9%。
03-13 07:17
财报速睇 | Mineralys Therapeutics 2025财年Q4营收0.00亿美元，同比增长0.0%；归母净利润亏损0.32亿美元，同比亏损缩窄34.7%
华盛资讯3月13日讯，Mineralys Therapeutics公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比增长0.0%，归母净利润亏损0.32亿美元，同比亏损缩窄34.7%。
03-13 05:02
Mineralys Therapeutics Q4 EPS $(0.40) Beats $(0.58) Estimate
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.58) by 30.68 percent. This is a 59.18 percent increase over losses of $(0.98) per share
03-13 04:08
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced the FDA acceptance of its NDA for lorundrostat to treat hypertension, with a PDUFA target date of December 22, 2026. The company reported strong financial results for 2025, ending the year with $656.6 million in cash, up from $198.2 million in 2024. Research and development expenses decreased by $36.6 million due to the completion of the lorundrostat pivotal program, while general and administrative expenses incre...
03-12 20:05
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Mineralys Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Eric Warren
Mineralys Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Eric Warren Mineralys Therapeutics, Inc. filed an initial statement of beneficial ownership reporting holdings for Eric Warren, Chief Commercial Officer. The full filing can be accessed through the link
03-05 08:25
